Opinions expressed by Entrepreneur contributors are their own.
In this fascinating episode of The Founder CEO, I had the opportunity to interview Howard Berman, Founder and CEO of Coya Therapeutics. Howard tells us the incredible story behind the founding of Coya Therapeutics, which was born out of a very personal family experience. We delve into his growth as a business leader and explore his mission-driven approach to healthcare innovation, as well as the challenges and successes of taking a biotech company public. Howard’s insights into the complexities of neurodegenerative diseases and the future of therapeutic development are truly inspiring. Don’t miss this dynamic conversation that highlights the future of healthcare.
Watch the full video interview with the founding CEO above and check out the key takeaways below.
RELATED: “Don’t just hand over the job, do the job”: How this women’s health care CEO leads with passion
Personal influences and family background
- Howard’s mother was a world-renowned cancer prevention expert and his father was a triple-board board-certified physician, deeply influencing his mission-driven approach.
- The founding of Coya Therapeutics was closely linked to Howard’s father’s diagnosis with dementia and subsequent death.
Founding challenges and milestones:
- The idea for Coya came from Howard’s collaboration with Dr. Stan Appel, a leading expert in neurodegenerative diseases.
- The company’s founding coincided with personal tragedy: Howard’s father died the same week Koya went public.
Mission-Driven Approach:
- Coya Therapeutics is working to develop therapies for neurodegenerative diseases that target inflammation via regulatory T cells (Tregs).
RELATED: How battling cancer influenced this founder’s patient care solutions
The Complexity of Neurodegenerative Disease:
- Howard emphasized that diseases such as ALS and dementia are complex, and effective treatments require targeting multiple pathways.
- Traditional single-mechanism drugs often fail, highlighting the need for innovative, multi-targeted approaches.
Innovation and Therapeutic Development:
- Coya’s unique approach involves administering two drugs simultaneously to address the multifaceted nature of neurodegenerative disease.
- The goal is to prove the effectiveness and safety of these treatments through rigorous clinical trials.
Biotech Market Challenges:
- To navigate the biotech market, especially in challenging times like 2022, required a bold and innovative strategy to secure funding and achieve IPO status.
Resilience and leadership evolution:
- Howard’s journey from visionary entrepreneur to CEO of a publicly traded company involved overcoming significant obstacles and learning to rely on a talented team.
- His leadership style emphasizes collaboration and trusting experts in their fields to drive the company’s success.
Strategic Growth and Team Building:
- Hiring the best talent and fostering a collaborative environment has been crucial to Coya’s progress.
- Howard’s experience highlights the importance of adapting leadership strategies to meet a company’s changing needs.
Coya Therapeutics’ Future Vision:
- Howard is committed to proving Coya 302 effective in treating Lou Gehrig’s disease and expanding its application to other neurodegenerative diseases, such as Alzheimer’s.
- Strategic collaborations with other pharmaceutical companies are part of Coya’s growth plans to accelerate drug development.
Howard Berman’s personal story is inspiring. His resilience as a person and an entrepreneur shines through in his story. These lessons serve as a reminder to other founders and CEOs about all the challenges and successes that come with starting and running your own business.
Related: Leadership lessons we can learn from the sudden and chaotic closures of two popular chains
